| NCT05630183 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-03-27 | 2025-12-05 | 2025-12-05 |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-12-12 | 2028-02 | 2028-02 |
| NCT05608044 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-11-30 | 2029-09 | 2027-09 |
| NCT05377528 | Study of AGEN1571 in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2022-07-19 | 2024-12-23 | 2024-12-23 |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | WITHDRAWN | PHASE2 | 2021-10-01 | 2024-12-30 | 2024-12-30 |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | WITHDRAWN | PHASE3 | 2021-08-02 | 2021-10-22 | 2021-10-22 |
| NCT04607200 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | WITHDRAWN | PHASE2 | 2021-02 | 2021-09-13 | 2021-09-13 |
| NCT04156100 | A Study in Subjects With Advanced Solid Tumors | TERMINATED | PHASE1 | 2019-12-10 | 2021-09-29 | 2021-04-08 |
| NCT04121676 | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | COMPLETED | PHASE1 | 2019-09-26 | 2024-11-30 | 2024-02-22 |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-06-01 | 2026-09 | 2025-08 |
| NCT03673020 | Phase 1a Study to Evaluate Immunogenicity of ASV® | COMPLETED | PHASE1 | 2019-05-16 | 2021-02-03 | 2021-02-03 |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-03-20 | 2027-12 | 2025-01-13 |
| NCT03495882 | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | COMPLETED | PHASE1, PHASE2 | 2017-12-18 | 2022-07-15 | 2022-07-15 |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | TERMINATED | PHASE2 | 2017-10-04 | 2019-03-01 | 2018-05-01 |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | COMPLETED | PHASE1, PHASE2 | 2017-04-11 | 2022-06-15 | 2022-06-15 |
| NCT02992977 | Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer | TERMINATED | PHASE1 | 2017-01 | 2019-12 | 2018-12 |
| NCT02694822 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | COMPLETED | PHASE1, PHASE2 | 2016-04 | 2022-03-31 | 2022-03-30 |
| NCT01687595 | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes | COMPLETED | PHASE2 | 2012-10-29 | 2015-01 | 2013-09 |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence | TERMINATED | PHASE2 | 2010-01 | 2012-06 | 2012-06 |
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | COMPLETED | PHASE1 | 2006-03 | | 2008-06 |
| NCT00231049 | Trial Evaluating Safety, Tolerability and Immune Response of AG-707 | COMPLETED | PHASE1 | 2006-03 | | |
| NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer | TERMINATED | PHASE3 | 2005-05 | 2006-03 | 2006-03 |
| NCT00098085 | Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer | COMPLETED | PHASE2 | 2003-09 | | 2007-11 |
| NCT00058747 | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ | TERMINATED | PHASE2 | 2003-03 | 2006-04 | 2006-04 |
| NCT00082459 | Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma | TERMINATED | PHASE2 | 2002-07 | 2005-12 | 2005-12 |
| NCT00039000 | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma | COMPLETED | PHASE3 | 2002-03 | 2005-12 | 2005-12 |
| NCT00033904 | Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer | COMPLETED | PHASE3 | 2000-06 | 2007-04 | 2007-04 |
| NCT00081809 | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma | COMPLETED | PHASE2 | 2000-03 | 2005-06 | 2005-06 |